<DOC>
	<DOCNO>NCT00975936</DOCNO>
	<brief_summary>This study methodology study evaluate microdose strategy Drug-Drug Interaction ( DDI ) useful evaluation backup compound GSK706769 , well possibly asset . The safety , tolerability pharmacokinetics evaluate healthy adult subject . This open-label fixed-sequence 2-period study healthy male volunteer oral administration [ 14C ] -GSK706769 alone presence Ketoconazole .</brief_summary>
	<brief_title>Phase 0 Microdose Study</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Males 1850 year age inclusive , time signing informed consent . AST , ALT , alkaline phosphatase bilirubin less equal 1.5x Upper Limit Normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Signed write informed consent prior begin studyrelated procedure . Subjects must understand aim , investigational procedure possible consequence study must able understand comply protocol requirement , instruction protocolstated restriction . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication 7 day postlast dose . Body weight great equal 50 kg ( 110 pound ) body mass index ( BMI ) 19 35 kg/m2 ( inclusive ) Capable give write informed consent , include compliance requirement restriction list consent form . Average QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define protocol . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 14 day 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication ( include Ketoconazole ) , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Any medical surgical condition might significantly interfere gastrointestinal absorption , distribution , metabolism , excretion study drug ( eg , gastrectomy ) . Subjects involved 14C human research study within previous 12 month . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication completion study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Phase 0</keyword>
	<keyword>Microdose</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>Drug-Drug Interaction</keyword>
</DOC>